Simulations Plus, Inc. (NASDAQ:SLP) announced a quarterly dividend on Tuesday, October 13th, Zacks reports. Investors of record on Monday, October 26th will be given a dividend of 0.06 per share by the technology company on Monday, November 2nd. This represents a $0.24 dividend on an annualized basis and a dividend yield of 0.35%. The ex-dividend date of this dividend is Friday, October 23rd.
Simulations Plus has raised its dividend payment by 20.0% over the last three years and has raised its dividend annually for the last 1 consecutive years. Simulations Plus has a dividend payout ratio of 49.0% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Simulations Plus to earn $0.62 per share next year, which means the company should continue to be able to cover its $0.24 annual dividend with an expected future payout ratio of 38.7%.
Simulations Plus stock opened at $69.50 on Wednesday. The stock has a market capitalization of $1.24 billion, a PE ratio of 139.00, a price-to-earnings-growth ratio of 6.76 and a beta of -0.19. Simulations Plus has a twelve month low of $26.00 and a twelve month high of $77.89. The company has a 50 day moving average of $67.85 and a 200-day moving average of $55.68.
In other news, Director Walter S. Woltosz sold 24,000 shares of the stock in a transaction dated Thursday, September 24th. The shares were sold at an average price of $66.08, for a total value of $1,585,920.00. Following the transaction, the director now directly owns 4,731,359 shares of the company’s stock, valued at $312,648,202.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 28.96% of the stock is owned by corporate insiders.
About Simulations Plus
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and machine-learning-based prediction of properties of molecules from their structure worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments that measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
See Also: How liquidity affects the bid-ask spread
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.